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bjectives The aim of this study was to evaluate long-term outcome of patients treated for in-stent
estenosis of bare-metal stents (BMS).
ackground Treatment of restenosis of BMS is characterized by high recurrence rates. Vascular
rachytherapy (VBT) improved outcome although late catch-up events were documented. Drug-
luting stents tested against VBT in this setting were found superior for at least the ﬁrst year; supe-
iority at longer follow-up is uncertain.
ethods We evaluated 3-year outcome of the multicenter SISR (Sirolimus-Eluting Stents Versus Vas-
ular Brachytherapy for In-Stent Restenosis) trial, which randomized patients with restenosis of BMS
o either a sirolimus-eluting stents (SES) or VBT.
esults Target vessel failure (cardiac death, infarction, or target vessel revascularization [TVR]) at 9
onths as previously reported was signiﬁcantly improved with SES. Kaplan-Meier analysis at 3 years
ocumented that survival free from target lesion revascularization (TLR) and TVR continues to be
igniﬁcantly improved with SES: freedom from TLR 81.0% versus 71.6% (log-rank p  0.018), and
VR 78.2% versus 68.8% (log-rank p  0.022), SES versus VBT. At 3 years, target vessel failure and
ajor adverse cardiac events (death, infarction, emergency coronary artery bypass grafting, or re-
eat TLR) remained improved with SES, but did not reach statistical signiﬁcance. There was no sta-
istically signiﬁcant difference in deﬁnite or probable stent thrombosis (3.5% for SES, 2.4% for VBT;
 0.758).
onclusions At 3 years of follow-up, after treatment of in-stent restenosis of BMS, patients treated
ith SES have improved survival free of TLR and TVR compared with patients treated with VBT.
tent thrombosis rates are not different between the 2 groups but are higher than reported in trials
f treatment of de novo lesions. (J Am Coll Cardiol Intv 2008;1:439–48) © 2008 by the American
ollege of Cardiology Foundation
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440n patients with complex coronary anatomy who are treated
ith drug-eluting stents (DES), follow-up is less well
escribed than in the patients initially treated in randomized
linical trials that included highly selected patients and
esions (1–3). Long-term follow-up of these “off-label”
ndications is of great interest.
A particularly high-risk group of patients/lesions include
hose with restenosis within a bare-metal stent. This prob-
em was extremely resistant to conventional treatment and
nally resulted in the development and approval of vascular
rachytherapy (VBT) (4–12). While VBT was initially very
ffective, several issues emerged (7–12). These included a
ate catch-up phenomenon, whereby the initial benefit of
educed restenosis gradually lost significance after the first
ear. In the 5-year follow-up of the SCRIPPS (Scripps
oronary Radiation to Inhibit Proliferation Post Stenting)
rial, there was loss in initial clinical efficacy over time so
that 74% reduction in freedom
from target lesion revasculariza-
tion (TLR) at 6 months de-
creased to 48% reduction at 5
years, and the minimal lumen
diameter of the treated segment
decreased from 2.49 at 6 months
to 2.12 at 36 months (13). In
addition, the problem of stent
thrombosis was raised, particu-
larly if a new bare-metal stent
was placed at the time of VBT.
These problems, among others,
led to the evaluation of DES to
treat this problem (14–22).
Several randomized trials of
VBT versus DES were under-
taken. In the 2 largest trials,
SISR (Sirolimus-Eluting Stents
Versus Vascular Brachytherapy
or In-Stent Restenosis) (14) and TAXUS V (15), patients
ere randomized to either a Cypher stent or to VBT. In the
ISR trial (14), the 9-month primary end point of target
essel failure (TVF) was significantly reduced with
irolimus-eluting stents (SES) from 21.6% to 12.4% (p 
.023). Stent thrombosis at 9 months was not reported with
BT but was 0.8% with SES (2 patients). Similarly, in the
AXUS V trial (15), a significant beneficial effect with
aclitaxel-eluting stents compared with VBT was seen with
reduction in 9-month TVF from 20.1% to 11.5% (p 
.03). In this latter study, target vessel thrombosis was seen
n 3 patients in the paclitaxel-eluting stent group (1.5%)
ersus 5 in the VBT group (2.6%; p  0.72).
Subsequent to these pivotal trials, there has been more
ttention paid to late adverse events such as death, myocar-
ial infarction (MI), and stent thrombosis (23–29) as well as
bbreviations
nd Acronyms
RC  academic research
onsortium
ES  drug-eluting stent(s)
ACE  major adverse
ardiac events
I  myocardial infarction
ES  sirolimus-eluting
tent(s)
LR  target lesion
evascularization
VF  target vessel failure
VR  target vessel
evascularization
BT  vascular
rachytherapynterest in whether late “catch-up” (13) with subsequentenarrowing would be observed with DES for this high-risk
roup of patients. This report extends the follow-up of the
ISR trial to 3 years with specific attention to late mortality,
I, stent thrombosis, antiplatelet medication use, and the
eed for repeat target vessel intervention.
ethods
he trial design and the primary end point of the SISR trial
ave been previously reported (Table 1) (14). In brief, this
ulticenter prospective 2-arm institutional review board-
pproved randomized trial evaluated the safety and efficacy
f SES compared with VBT for the treatment of in-stent
estenosis occurring after implantation of a bare-metal stent.
he primary end point was TVF defined as cardiac death,
I, or target vessel revascularization (TVR) at 9 months
ost-procedure. Entry criteria included patients undergoing
linically indicated revascularization of bare-metal in-stent
estenotic native coronary lesions 15 mm but 40 mm in
ength and in vessels 2.5 mm but 3.5 mm in diameter.
atients with recent MI or unstable angina, complete
cclusion of the in-stent restenotic segment, or planned
ntervention of another lesion within 30 days of the study
rocedure were excluded. All patients signed a consent
orm.
Vascular brachytherapy was performed with either
amma or beta sources. The lesion was pre-dilated and then
adiation applied to the target lesion with a 5-mm margin
n either side. Placement of a new stent in association with
he VBT procedure was strongly discouraged because this
ad been previously shown to increase late thrombosis. In
he SES arm, pre-dilation was also performed. The DES
as selected to cover the initial lesion and more than 3 mm
eyond both ends of the region of pre-dilation balloon
ngioplasty, optimizing stent coverage from the angio-
raphically normal vessel proximal to distal. It was required
hat the restenotic segment be fully covered although it was
ot required that the entire region initially covered by the
are-metal stent be restented. Study medications included
he following:
. Pre-procedure: aspirin 325 mg was administered 24 h
before the procedure and thienopyridine either ticlopi-
dine or clopidogrel administered with a loading dose
before or immediately after the procedure.
. Intraprocedure: heparin with an intravenous bolus to
achieve and maintain an activated clotting time of
approximately 250 s if a glycoprotein IIb/IIIa inhibitor
was administered or 300 to 350 s if no glycoprotein
IIb/IIIa inhibitor was used. Administration of a glyco-
protein IIb/IIIa inhibitor was at the operator’s discretion.
. Post-procedure: aspirin 325 mg a day and a thienopyridine
3 months in the sirolimus-eluting limb or 6 months
in the VBT group if a new stent was not placed (90% of
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441patients) or 12 months in the VBT limb if a new stent
was placed. The recommendation for a thienopyridine
administered for 3 months in the sirolimus limb was
based on the initial instructions for use after product
approval.
Stent thrombosis was defined per study protocol as the
nding of angiographic thrombus within the stented vessel
t the time of clinically driven angiographic restudy for
ocumented ischemia with abrupt or subacute closure of the
reated segment. Angiographic stent thrombosis requiring
LR during the first 30 days after the index stent placement
as considered as an end point for the combined 30-day
schemic end point. Any death not attributable to a non-
ardiac cause or any Q-wave MI in the territory of the
tented vessel within the first 30 days after stent implanta-
ion was considered a surrogate for stent thrombosis.
Stent thrombosis was also evaluated post hoc by the
linical events committee using the recently described aca-
emic research consortium (ARC) definitions (30). These
efinitions identify timing of the event as acute stent
hrombosis 0 to 24 h after stent implantation, subacute
hrombosis 24 h to 30 days after stent implantation, late
tent thrombosis at 30 days to 1 year after stent implanta-
ion, and very late stent thrombosis1 year after index stent
mplantation. The ARC definition includes definite stent
hrombosis if there is: 1) Thrombolysis In Myocardial
nfarction (TIMI) flow grade 0 with an occlusion originat-
ng in the stent or in a segment 5 mm proximal or distal to
he stent region in the presence of thrombus; or 2) TIMI
ow grade 1, 2, or 3 originating in the stent or in the
egment 5 mm proximal or distal to the region with
ngiographic documentation of thrombus, when it occurs in
he setting of either new onset of ischemic symptoms at rest,
Table 1. 9-Month Follow-Up and Primary End Point
Adverse Events
Vascular Brachytherapy
(n  125)
Major adverse clinical event 24 (19.2)
Death 0 (0.0)
Myocardial infarction 0 (0.0)
Q-wave 0 (0.0)
Non–Q-wave 0 (0.0)
Emergent CABG surgery 0 (0.0)
Target lesion revascularization 24 (19.2)
Target lesion CABG surgery 6 (4.8)
Target lesion PTCA 20 (16.0)
Target vessel revascularization 27 (21.6)
Target vessel failure 27 (21.6)
Stent thrombosis 0 (0.0)
Late stent thrombosis 0 (0.0)
*Relative risk could not be calculated due to zero cell. Values are n (%) of patients.
CABG coronary artery bypass grafting; CI confidence interval; PTCA percutaneous coronaew ischemic electrocardiogram changes, or a typical rise and fall in cardiac biomarkers. The ARC definition of
robable stent thrombosis is any unexplained death within
he first 30 days after the index procedure, or any MI in the
bsence of an obvious cause, which is in the territory of the
mplanted stent without angiographic confirmation of a
tent thrombosis. Possible stent thrombosis is defined as any
nexplained death beyond 30 days.
ata collection follow-up and core laboratory analysis. Base-
ine and clinical data were collected on standard case report
orms by the clinical investigators at the clinical sites. Data
ere submitted to the data coordinating center (Harvard
linical Research Institute, Harvard Medical School, Bos-
on, Massachusetts). Clinical end points were adjudicated
y an independent clinical events committee blinded to
tudy group assignment. A separate data and safety moni-
oring board not affiliated with either the study sponsor or
he investigators reviewed data periodically throughout the
rial to identify potential safety issues and monitor study
onduct. The data presented herein represent all angio-
raphic and clinical follow-up data available as of October 4,
007.
tatistical analysis. Safety evaluation and effectiveness anal-
sis was performed on an intent-to-treat basis. This study
as designed to demonstrate the noninferiority or superi-
rity of the Cypher stent (Cordis, Warren, New Jersey)
ompared with intracoronary VBT for the primary end
oint, TVF. Noninferiority was expected based on docu-
ented safety and efficacy with both approaches. Superior-
ty was expected due to significant reduction in TLR due to
n improvement in analysis segment net gain and late lumen
oss in previous studies with the SES. The trial was designed
nd powered for the 9-month primary end point; while no
pecific hypothesis was pre-specified for longer-term evalu-
Sirolimus-Eluting Stent
(n  259)
Relative Risk
(95% CI) p Value
26 (10.0) 1.9 (1.1–3.2) 0.02
0 (0.0) *
6 (2.3) * 0.18
1 (0.4) * 0.99
6 (2.3) * 0.18
0 (0.0) *
22 (8.5) 2.3 (1.3–3.9) 0.004
1 (0.4) 12.4 (1.5–102.2) 0.006
21 (8.1) 2.0 (1.1–3.5) 0.02
28 (10.8) 2.0 (1.2–3.2) 0.008
32 (12.4) 1.7 (1.1–2.8) 0.02
0 (0.0) *
2 (0.8) * 0.99
plasty.tion, follow-up was pre-specified for the first year after
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442reatment and then yearly thereafter to a total of 5 years.
hus, the statistics for these later time points are descrip-
ive. No patients were censored at the time of reinterven-
ion, but rather were censored for lost-to-follow status
efore the analyzed event was observed or no analyzed event
as observed at the end of the analysis period (i.e., 1,080
ays after index procedure). If a patient had multiple
epeated interventions, that patient was considered to have
n analyzed reintervention event at the earliest occurrence
fter index procedure. All event rates are estimated using
aplan-Meier analysis, which partially adjusts for patients
ost to follow-up. The analyses at 9 months and 3 years were
elatively independent of each other, and the conclusion that
as drawn from the 3-year follow-up data was not condi-
ioned to the conclusion of the 9-months results.
Since the trial was neither powered nor designed for
ong-term follow-up, the focus of this longer-term
ollow-up involved an examination of the pre-specified
afety end points of death, MI, and stent thrombosis and an
valuation of the efficacy end point of TLR to determine
hether any new safety issues emerged with subsequent
ollow-up and whether the major benefit of SES, namely
eduction in TLR, was maintained. The analyzed events
ere adjudicated by independent Clinical Events Commit-
Table 2. In- and Out-of-Hospital Complications Out to 3 Years—All Patients
Nonhierarchical Complications to 1,080 Days
Vascular
Brachytherapy
(n  125)
MACE (death, Q- or non–Q-wave MI, emergency CABG, TLR) 28.0% (35/125)
Death 2.4% (3/125)
Cardiac 0.8% (1/125)
Noncardiac 1.6% (2/125)
MI (Q- or WHO non–Q-wave) 3.2% (4/125)
All Q-wave MI 0.0% (0/125)
TV Q-wave MI 0.0% (0/125)
Non-TV Q-wave MI 0.0% (0/125)
All WHO non–Q-wave MI 3.2% (4/125)
TV WHO non–Q-wave MI 3.2% (4/125)
Non-TV WHO non–Q-wave MI 0.0% (0/125)
All TV MI (Q- or WHO non–Q-wave MI) 3.2% (4/125)
All non-TV MI (Q or WHO non–Q-wave MI) 0.0% (0/125)
Emergent CABG 0.0% (0/125)
TL revascularization 26.4% (33/125)
TL-CABG 6.4% (8/125)
TL-PTCA 23.2% (29/125)
TV revascularization not involving TL 8.8% (11/125)
TV/non–TL-CABG 2.4% (3/125)
TV/non–TL-PTCA 7.2% (9/125)
TV failure to 270 days (primary end point) 21.6% (27/125)
TV failure to 1,080 days 30.4% (38/125)
TV revascularization (all) 29.6% (37/125)
MACEmajor adverse cardiac events; MImyocardial infarction; TL target lesion; TLR targetTable 1.ee members who were blinded to the treatment assignment
hen the events were adjudicated, and, therefore, no other
ensoring method was applied.
esults
rom February 12, 2003 through July 27, 2004, 384 patients
ere enrolled at 26 centers and randomized to treatment
ith VBT (n  125) or the SES (n  259). Compliance to
ollow-up at 1,080 days (3 years) was similar in both groups
t 88.0% for VBT (110 of 125) and 91.9% of SES patients
238 of 259).
Examination of data to 3 years demonstrated no safety
ssues in either arm. No differences were observed in the
requency of death, MI, or protocol-defined stent throm-
osis between the VBT and SES arms to 3 years (Tables 2
nd 3). Further examination of the adjudicated end points
f cardiac death, noncardiac death, Q-wave MI, non–Q-
ave MI, and stent thrombosis using the ARC definitions
lso failed to demonstrate any significant differences be-
ween the VBT and SES groups. In total, these end points
ere infrequent, and the increment per year in the rates of
eath, MI, and stent thrombosis was similar between the 2
roups. No Q-wave MIs at 3 years were observed in the
rolimus-
ing Stent
 259)
All Patients
(n  384 Patients,
n  384 Lesions)
Difference
(95% CI) p Value
% (61/259) 25.0% (96/384) 4.4% (4.6% to 14.1%) 0.379
% (10/259) 3.4% (13/384) 1.5% (4.9% to 3.3%) 0.560
% (4/259) 1.3% (5/384) 0.7% (3.2% to 3.0%) 1.000
% (6/259) 2.1% (8/384) 0.7% (3.6% to 3.5%) 1.000
% (16/259) 5.2% (20/384) 3.0% (7.1% to 2.3%) 0.327
% (4/259) 1.0% (4/384) 1.5% (3.9% to 1.6%) 0.309
% (4/259) 1.0% (4/384) 1.5% (3.9% to 1.6%) 0.309
% (0/259) 0.0% (0/384) 0.0% (1.5% to 3.0%) —
% (14/259) 4.7% (18/384) 2.2% (6.2% to 3.0%) 0.444
% (13/259) 4.4% (17/384) 1.8% (5.7% to 3.3%) 0.598
% (1/259) 0.3% (1/384) 0.4% (2.2% to 2.6%) 1.000
% (15/259) 4.9% (19/384) 2.6% (6.6% to 2.7%) 0.325
% (1/259) 0.3% (1/384) 0.4% (2.2% to 2.6%) 1.000
% (0/259) 0.0% (0/384) 0.0% (1.5% to 3.0%) —
% (46/259) 20.6% (79/384) 8.6% (0.0% to 18.0%) 0.059
% (8/259) 4.2% (16/384) 3.3% (0.9% to 9.2%) 0.171
% (41/259) 18.2% (70/384) 7.4% (0.8% to 16.4%) 0.091
% (18/259) 7.6% (29/384) 1.9% (3.5% to 8.6%) 0.540
% (1/259) 1.0% (4/384) 2.0% (0.4% to 6.4%) 0.103
% (17/259) 6.8% (26/384) 0.6% (4.4% to 7.0%) 0.830
% (32/259) 15.4% (59/384) 9.2% (1.5% to 18.0%) 0.023
% (62/259) 26.0% (100/384) 6.5% (2.8% to 16.3%) 0.214
% (54/259) 23.7% (91/384) 8.8% (0.3% to 18.4%) 0.073
evascularization; TV target vessel; WHOWorld Health Organization; other abbreviations as inSi
Elut
(n
23.6
3.9
1.5
2.3
6.2
1.5
1.5
0.0
5.4
5.0
0.4
5.8
0.4
0.0
17.8
3.1
15.8
6.9
0.4
6.6
12.4
23.9
20.8
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443BT group while a low frequency was observed in the SES
roup (4 of 259 or 1.5%).
While the trial was neither designed nor powered to
xamine efficacy end points or composite safety and efficacy
nd points beyond the 9-month time primary end point
eriod, it is instructive to examine changes in both TLR
Fig. 1) and TVR (Fig. 2) as well as TVF (Fig. 3) and major
dverse cardiac events (MACE) with time. Using Kaplan-
eier analysis, survival free from TLR and TVR at 3 years
emonstrates that patients treated with SES show a signif-
cant improvement as compared with patients treated with
BT (TLR: 81.0% vs. 71.6%, log-rank p  0.018; TVR:
Table 3. Summary of Protocol and ARC Stent Thrombosis (to 1,080 Days)—
Events to 1,080 Days
Vascular Brachytherapy Sirolimus-Elu
(n  125) 95% CI (n  259)
Protocol thrombosis
Acute thrombosis (0–1) 0.0% (0/125) (0.0% to 2.9%) 0.0% (0/259) (
Subacute thrombosis (2–30) 0.0% (0/125) (0.0% to 2.9%) 0.0% (0/259) (
Late thrombosis (31–360) 0.0% (0/125) (0.0% to 2.9%) 1.2% (3/259) (
Very late thrombosis
(361–1,080)
0.8% (1/125) (0.0% to 4.4%) 0.8% (2/259) (
All thrombosis (0–1,080) 0.8% (1/125) (0.0% to 4.4%) 1.9% (5/259) (
Any ARC thrombosis
Acute thrombosis (0–1) 0.0% (0/125) (0.0% to 2.9%) 0.0% (0/259) (
Subacute thrombosis (2–30) 0.0% (0/125) (0.0% to 2.9%) 0.0% (0/259) (
Late thrombosis (31–360) 0.8% (1/125) (0.0% to 4.4%) 1.5% (4/259) (
Very late thrombosis
(361–1,080)
2.4% (3/125) (0.5% to 6.9%) 3.1% (8/259) (
All thrombosis (0–1,080) 2.4% (3/125) (0.5% to 6.9%) 4.2% (11/259) (
Deﬁnite or probable ARC
thrombosis
Acute thrombosis (0–1) 0.0% (0/125) (0.0% to 2.9%) 0.0% (0/259) (
Subacute thrombosis (2–30) 0.0% (0/125) (0.0% to 2.9%) 0.0% (0/259) (
Late thrombosis (31–360) 0.8% (1/125) (0.0% to 4.4%) 1.5% (4/259) (
Very late thrombosis
(361–1,080)
2.4% (3/125) (0.5% to 6.9%) 2.3% (6/259) (
All thrombosis (0–1,080) 2.4% (3/125) (0.5% to 6.9%) 3.5% (9/259) (
Deﬁnite ARC thrombosis
Acute Thrombosis (0–1) 0.0% (0/125) (0.0% to 2.9%) 0.0% (0/259) (
Subacute thrombosis (2–30) 0.0% (0/125) (0.0% to 2.9%) 0.0% (0/259) (
Late thrombosis (31–360) 0.0% (0/125) (0.0% to 2.9%) 1.5% (4/259) (
Very late thrombosis
(361–1,080)
2.4% (3/125) (0.5% to 6.9%) 1.5% (4/259) (
All thrombosis (0–1,080) 2.4% (3/125) (0.5% to 6.9%) 2.7% (7/259) (
Probable ARC thrombosis
Acute thrombosis (0–1) 0.0% (0/125) (0.0% to 2.9%) 0.0% (0/259) (
Subacute thrombosis (2–30) 0.0% (0/125) (0.0% to 2.9%) 0.0% (0/259) (
Late thrombosis (31–360) 0.8% (1/125) (0.0% to 4.4%) 0.0% (0/259) (
Very late thrombosis
(361–1,080)
0.0% (0/125) (0.0% to 2.9%) 0.8% (2/259) (
All thrombosis (0–1,080) 0.8% (1/125) (0.0% to 4.4%) 0.8% (2/259) (
ARC academic research consortium; CI confidence interval.8.2% vs. 68.8%, log-rank p 0.022) (Figs. 1 and 2). There oere, however, no differences in survival free from TVF or
ACE at 3 years (TVF: 75.1% vs. 67.9%, log-rank p 
.087; MACE: 75.5% vs. 70.5%, log-rank p 0.186) (Figs.
and 4) (SES vs. VBT).
Using the protocol definition, stent thrombosis was
djudicated in 6 patients: 1 patient in the VBT group (1 of
25 or 0.8%) and 5 patients in the SES group (5 of 259 or
.9%, p  0.668) (Table 2). At the time of the stent
hrombosis, the VBT patient was taking clopidogrel, but
ot aspirin, and 4 of the 5 SES patients were taking aspirin,
ut not clopidogrel.
Adjudicated using the ARC definition, the total number
atients
tent
All Patients
Difference
(95% CI) p ValueCI
(n  384 Patients,
n  384 Lesions) 95% CI
o 1.4%) 0.0% (0/384) (0.0% to 1.0%) 0.0% (1.5% to 3.0%) —
o 1.4%) 0.0% (0/384) (0.0% to 1.0%) 0.0% (1.5% to 3.0%) —
o 3.3%) 0.8% (3/384) (0.2% to 2.3%) 1.2% (3.3% to 1.9%) 0.554
o 2.8%) 0.8% (3/384) (0.2% to 2.3%) 0.0% (2.1% to 3.7%) 1.000
o 4.4%) 1.6% (6/384) (0.6% to 3.4%) 1.1% (3.7% to 2.6%) 0.668
o 1.4%) 0.0% (0/384) (0.0% to 1.0%) 0.0% (1.5% to 3.0%) —
o 1.4%) 0.0% (0/384) (0.0% to 1.0%) 0.0% (1.5% to 3.0%) —
o 3.9%) 1.3% (5/384) (0.4% to 3.0%) 0.7% (3.2% to 3.0%) 1.000
o 6.0%) 2.9% (11/384) (1.4% to 5.1%) 0.7% (4.0% to 4.0%) 1.000
o 7.5%) 3.6% (14/384) (2.0% to 6.0%) 1.8% (5.4% to 2.9%) 0.562
o 1.4%) 0.0% (0/384) (0.0% to 1.0%) 0.0% (1.5% to 3.0%) —
o 1.4%) 0.0% (0/384) (0.0% to 1.0%) 0.0% (1.5% to 3.0%) —
o 3.9%) 1.3% (5/384) (0.4% to 3.0%) 0.7% (3.2% to 3.0%) 1.000
o 5.0%) 2.3% (9/384) (1.1% to 4.4%) 0.1% (3.0% to 4.7%) 1.000
o 6.5%) 3.1% (12/384) (1.6% to 5.4%) 1.1% (4.5% to 3.6%) 0.758
o 1.4%) 0.0% (0/384) (0.0% to 1.0%) 0.0% (1.5% to 3.0%) —
o 1.4%) 0.0% (0/384) (0.0% to 1.0%) 0.0% (1.5% to 3.0%) —
o 3.9%) 1.0% (4/384) (0.3% to 2.6%) 1.5% (3.9% to 1.6%) 0.309
o 3.9%) 1.8% (7/384) (0.7% to 3.7%) 0.9% (2.0% to 5.4%) 0.687
o 5.5%) 2.6% (10/384) (1.3% to 4.7%) 0.3% (3.5% to 4.3%) 1.000
o 1.4%) 0.0% (0/384) (0.0% to 1.0%) 0.0% (1.5% to 3.0%) —
o 1.4%) 0.0% (0/384) (0.0% to 1.0%) 0.0% (1.5% to 3.0%) —
o 1.4%) 0.3% (1/384) (0.0% to 1.4%) 0.8% (0.8% to 4.4%) 0.326
o 2.8%) 0.5% (2/384) (0.1% to 1.9%) 0.8% (2.8% to 2.3%) 1.000
o 2.8%) 0.8% (3/384) (0.2% to 2.3%) 0.0% (2.1% to 3.7%) 1.000All P
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444he per-protocol definition, but there was no significant
ifference between VBT and SES. Using the definition of
any ARC thrombosis,” this occurred in 2.4% for VBT
ersus 4.2% for SES (p  0.562). Using the definition of
definite or probable thrombosis,” the difference was less,
.4% versus 3.5% (p  0.758). Irrespective of what defini-
ion was used, stent thrombosis was observed most fre-
uently very late, after the first year of follow-up in both
roups. At the time of ARC-defined stent thrombosis, 4 of
patients identified as having “definite” ARC stent throm-
Figure 1. Kaplan-Meier Curves and Survival Table for the End Point of
TLR to 1,080 Days
In patients treated with the Cypher stent (Cordis), freedom from target
lesion revascularization (TLR) remains signiﬁcantly better than vascular
brachytherapy throughout the 3-year follow-up period (log-rank p 
0.018).
Figure 2. Kaplan-Meier Curves and Survival Table for the End Point of TVR
In patients treated with the Cypher stent (Cordis), freedom from target vessel
throughout the 3-year follow-up period (log-rank p  0.022).osis were taking both aspirin and clopidogrel, while 5 of
hose 9 patients were taking neither drug. Of the 3 patients
ith “probable” ARC stent thrombosis, 1 patient was taking
oth drugs, 1 was taking aspirin but not clopidogrel, and 1
as taking neither drug. Of the 2 patients identified as
aving “possible” stent thrombosis, 1 patient was on both
edications, while the other was taking clopidogrel, but not
spirin. Thus, for patients with stent thrombosis identified
sing the protocol definition, almost all of the patients were
ot taking either Plavix (Bristol-Myers Squibb/Sanofi Phar-
aceuticals Partnership, Bridgewater, New Jersey) or aspi-
in; for stent thrombosis patients identified using the ARC
efinitions, approximately one-half were on both antiplate-
et drugs and one-half were not taking either antiplatelet
rug.
In putting these data in perspective, it is useful to
emember that only 6 (VBT) and 3 (SES) months of dual
ntiplatelet therapy were recommended per protocol. Actual
edication use was more prolonged than these recommen-
ations (Table 4). Continued dual antiplatelet medication
se was high and quite similar in both arms through 3 years
f follow-up (Table 4) despite these different recommended
urations of treatment. At hospital discharge and during
ollow-up to the primary end point at 9 months, dual
ntiplatelet medication use was reported in 61% of pa-
ients, and more than one-half of the remaining 39% of
atients received either aspirin or a thienopyridine agent as
ingle drug therapy; only 15.2% of VBT and 7.7% of SES
atients were not on any oral antiplatelet agent. From 9
onths to 3 years, antiplatelet medication was not protocol
andated; use of these medications still remained fairly
80 Days
ularization (TVR) remains signiﬁcantly better than vascular brachytherapyto 1,0
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445igh so that by year 3 of follow-up, approximately 56.7% of
atients were on dual antiplatelet therapy whereas 19.5% of
atients were not on any antiplatelet regimen.
iscussion
hile trials are designed and powered to test a pre-defined
rimary end point, long-term follow-up is useful in identi-
ying any late safety signals that may emerge after ascertain-
ent of the primary end point and in providing insight into
he preservation of the initially measured clinical benefit.
rogression of disease and further intervention or treatment
hat does not follow the randomization scheme can either
ncrease event rates and/or introduce random effects, or
oth, which can complicate proper interpretation of late
ollow-up findings.
Nevertheless, there are several important findings evident
n the data generated from the intermediate 3-year
ollow-up of the SISR trial (14) comparing SES and VBT
or the treatment of in-stent restenosis of bare-metal stents,
ncluding: 1) at 3 years, safety end points such as all death,
ardiac death, all MI, Q-wave MI, and non–Q-wave MI
emain infrequent and do not suggest that a safety signal has
merged in either the VBT or SES arms; 2) stent throm-
osis remains relatively uncommon but is clearly increased
ompared with that seen in patients treated with SES for de
ovo lesions. There was, however, no significant difference
etween SES and VBT groups; 3) continued use of dual
ntiplatelet therapy at 3 years remains high (60%) with
nly 20% of patients receiving no oral antiplatelet agent;
) differences in oral antiplatelet drug use were notable for
atients with protocol-defined stent thrombosis, but not for
Figure 3. Kaplan-Meier Curves and Survival Table for the End Point of
TVF to 1,080 Days
In patients treated with the Cypher stent (Cordis), the difference in free-
dom from target lesion revascularization from vascular brachytherapy is
attenuated throughout the 3-year follow-up period (log-rank p  0.087).
TVF  target vessel failure.atients with ARC-defined stent thrombosis; 5) superiorityf SES over VBT is maintained when restricted to the
fficacy end points of TLR and TVR; and 6) rates of TVF
nd MACE are no longer different between the control and
xperimental arms.
These findings have significant implications. First, both
reatment modalities studied in this trial demonstrated no
ew safety issues of death or infarction. While VBT
7–12,31) has virtually disappeared due to its cumbersome
quipment needs and due to the availability and widespread
se of DES, no differences in the safety outcomes of death
nd infarction were observed between SES and VBT. It
ppears that the use of prolonged dual antiplatelet therapy
nd avoidance of use of stenting at the time of VBT have
uccessfully eliminated the previously observed increased
requency of stent thrombosis with VBT. The maintenance
f a clinical benefit of SES over VBT when looking only at
he efficacy end points of TLR and TVR suggests both
mprovement of outcomes of SES over VBT but also a lack
f “late catch-up” as described in the VBT literature
8,12,31). Despite the finding that stent thrombosis was not
ignificantly different between SES and VBT, the absolute
ate of 3.5% is higher than seen with treatment of de novo
esions. This could have important implications. Finally,
espite a limited recommended duration of dual antiplatelet
se, a majority of patients in both arms were observed to
ave remained on or to have been restarted on this therapy.
hile this might be due to the desire to allow benefits to
atients with respect to the reduction in death, MI, and
troke by thienopyridine agents when used as medical
herapy in patients with coronary disease, it is more likely
hat this treatment has been maintained or restarted due to
oncerns about late stent thrombosis and the recommenda-
ions of professional groups such as the American Heart
ssociation, American College of Cardiology, Society for
Figure 4. Kaplan-Meier Curves and Survival Table for the End Point of
MACE to 1,080 Days
In patients treated with the Cypher stent (Cordis), the difference in major
adverse cardiac events (MACE) from vascular brachytherapy is attenuated
throughout the 3-year follow-up period (log-rank p  0.186)
C
E
a
(
e
n
r
t
d
b
l
a
m
f
i
a
E
c
T
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 4 , 2 0 0 8
A U G U S T 2 0 0 8 : 4 3 9 – 4 8
Holmes Jr. et al.
SISR Trial Follow-Up
446ardiovascular Angiography and Interventions, and the
uropean Society of Cardiology to use prolonged dual
ntiplatelet therapy in patients after deployment of a DES
32). Given the late stent thrombosis in this patient subset,
fforts at maintaining prolonged dual antiplatelet therapy
eed to be emphasized.
These results have assumed increased importance due to the
ecent shift in stent use from90% DES use in recent years to
he current 60% or lower DES use. The use of DES has
ecreased in part because of the potential of late stent throm-
Table 4. Medication Usage to 3 Years
Measure
Vascular Brachytherapy
(n  125)
Discharge
ASA  (clopidogrel or ticlopidine) 87.9% (226/257)
ASA only 0.0% (0/257)
Clopidogrel only 11.7% (30/257)
Ticlopidine only 0.0% (0/257)
None of the above 1.2% (3/259)
At 30-day follow-up
ASA  (clopidogrel or ticlopidine) 83.3% (210/252)
ASA only 1.6% (4/252)
Clopidogrel only 14.3% (36/252)
Ticlopidine only 0.0% (0/252)
None of the above 3.5% (9/259)
At 6-month follow-up
ASA  (clopidogrel or ticlopidine) 70.1% (176/251)
ASA only 6.8% (17/251)
Clopidogrel only 21.9% (55/251)
Ticlopidine only 0.0% (0/251)
None of the above 4.2% (11/259)
At 12-month follow-up
ASA  (clopidogrel or ticlopidine) 52.0% (127/244)
ASA only 21.7% (53/244)
Clopidogrel only 19.7% (48/244)
Ticlopidine only 0.0% (0/244)
None of the above 12.0% (31/259)
At 2-year follow-up
ASA  (clopidogrel or ticlopidine) 42.4% (100/236)
ASA only 25.4% (60/236)
Clopidogrel only 19.1% (45/236)
Ticlopidine only 0.0% (0/236)
None of the above 20.8% (54/259)
At 3-year follow-up
ASA  (clopidogrel or ticlopidine) 56.1% (128/228)
ASA only 30.3% (69/228)
Clopidogrel only 5.3% (12/228)
Ticlopidine only 0.0% (0/228)
None of the above 19.3% (50/259)
Per the protocol, the Cypher patients were to take acetylsalicylic acid (ASA) indefinitely and Plavix o
take ASA indefinitely. Those that received a stent during the procedure were to take Plavix or Ticlid
months. Patients may have more than 1 medication at each time point.osis and the recommended need for prolonged dual antiplate- ret therapy (23–27,32). Some institutions and regions, as well
s individual operators, have implemented a policy of the use of
ore frequent placement of bare-metal stents, using only DES
or more “complex” lesions. Taken to the extreme, Swedish
nvestigators (26) have recently adopted a policy that discour-
ges DES use, and the BASKET (Basel Stent Kosten-
ffektivitats Trial) stent trial investigators concluded that
urrent DES are not cost effective in many patients (33,34).
hese trends have led to an increase in the use of BMS, and,
hus, more BMS restenosis will probably be encountered in
Sirolimus-Eluting Stent
(n  259)
All Patients
(n  384 Patients,
n  384 Lesions) p Value
87.2% (109/125) 87.7% (335/382) 0.869
0.0% (0/125) 0.0% (0/382) —
12.0% (15/125) 11.8% (45/382) 1.000
0.8% (1/125) 0.3% (1/382) 0.327
0.0% (0/125) 0.8% (3/384) 0.554
86.3% (107/124) 84.3% (317/376) 0.547
2.4% (3/124) 1.9% (7/376) 0.689
9.7% (12/124) 12.8% (48/376) 0.251
0.8% (1/124) 0.3% (1/376) 0.330
1.6% (2/125) 2.9% (11/384) 0.515
75.0% (87/116) 71.7% (263/367) 0.384
5.2% (6/116) 6.3% (23/367) 0.649
15.5% (18/116) 19.9% (73/367) 0.163
0.9% (1/116) 0.3% (1/367) 0.316
10.4% (13/125) 6.3% (24/384) 0.025
55.7% (64/115) 53.2% (191/359) 0.571
16.5% (19/115) 20.1% (72/359) 0.263
20.0% (23/115) 19.8% (71/359) 1.000
0.9% (1/115) 0.3% (1/359) 0.320
14.4% (18/125) 12.8% (49/384) 0.516
41.2% (47/114) 42.0% (147/350) 0.908
23.7% (27/114) 24.9% (87/350) 0.792
18.4% (21/114) 18.9% (66/350) 1.000
0.0% (0/114) 0.0% (0/350) —
24.0% (30/125) 21.9% (84/384) 0.511
57.8% (63/109) 56.7% (191/337) 0.815
30.3% (33/109) 30.3% (102/337) 1.000
3.7% (4/109) 4.7% (16/337) 0.597
0.0% (0/109) 0.0% (0/337) —
20.0% (25/125) 19.5% (75/384) 0.891
(Bristol-Myers Squibb/Sanofi Pharmaceuticals) for at least 12 weeks. The radiation patients were to
ast 12 months. Those patients who did not receive a stent were to take Plavix or Ticlid for at least 6r Ticlid
for at leoutine clinical practice.
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447The treatment of restenosis occurring after placement of
are-metal stents has been problematic. Even though reste-
osis after bare-metal stents occurred less frequently than
fter conventional percutaneous transluminal coronary an-
ioplasty, it still resulted in clinical problems including
ecurrent ischemia, acute coronary syndromes, need for
epeat procedures, and, infrequently, death. Grading
chemes (35) were developed that could be used to assess
isk of subsequent events after restenosis of bare-metal
tents; using one of these algorithms, the rate of adverse
ubsequent events was as high as 80% to 90%.
Recently, more data have become available on the spec-
rum of events that occur in patients with restenosis of
are-metal stents (36–38). We recently reported on the
requency and outcome of stent thrombosis and restenosis
uring extended follow-up of 4,503 patients treated with at
east 1 bare-metal stent (36). Restenosis in these patients
ay present as acute infarction, and, when it does so, the
ortality is increased. In this patient cohort in the patients
ith restenosis at 10 years, 7.4% had experienced unstable
ngina and 2.1% had experienced an MI. Given the relative
requency of restenosis versus stent thrombosis, restenosis
vents accounted for more absolute deaths than did stent
hrombosis. Williams and Abbott (39) editorialized that “one
ight postulate that in-stent restenosis related MI would be
bserved less commonly among DES treated patients than
atients treated with a BMS” because DES is associated with
ess in-stent restenosis. Similarly, Chen et al. (38) evaluated
,186 patients with restenosis of bare-metal stents. They found
hat 36% presented as an MI or unstable angina. Of these, an
T-segment elevation MI was present in 2.2%. Nayak et al.
37) evaluated longer-term outcome in 2,462 patients under-
oing percutaneous transluminal coronary angioplasty with a
are-metal stent. Of patients with in-stent restenosis, 5%
resented with an ST-segment elevation MI.
Thus, strategies to avoid the occurrence of restenosis are
arranted. However, if restenosis is observed in the context
f prior treatment with a BMS, the 3-year follow-up data
rom the SISR trial suggest that SES appear to provide an
ffective and durable therapy that is devoid of new safety
ssues of death and infarction and that offer several advantages
ver the only other approved treatment for restenosis, namely
BT. However, the increase in stent thrombosis relative to
nitial treatment of de novo lesions remains of concern.
tudy limitations. The primary end point of this trial was
VF at 9 months. Follow-up after the primary end point
as yearly. The trial was not powered for long-term
ollow-up. This was of particular relevance for low-
requency events such as stent thrombosis. In addition,
pproximately 10% of patients were lost to follow-up. This
urrent follow-up analysis is descriptive and examines the
re-specified safety end points of death, MI, and stent
hrombosis as well as the efficacy end point of TLR. In
ddition, antiplatelet regimens after 9 months were notandated, and so they varied according to the clinical
ractice at participating sites.
onclusions
n the randomized SISR trial of SES versus VBT for
reatment of in-stent restenosis at 3 years: 1) the safety end
oint of death, cardiac death, and MI are infrequent and do
ot differ significantly between SES and VBT; 2) definite or
robable stent thrombosis was not significantly different
etween the 2 treatment regiments but was increased
elative to those rates seen with treatment of de novo
esions; and 3) SES remain superior in achieving the goal of
ecreasing the frequency of subsequent TLR and TVR.
eprint requests and correspondence: Dr. David R. Holmes Jr.,
ayo Clinic, 200 First Street SW, SMH MB 4-523, Rochester,
innesota 55905. E-mail: holmes.david@mayo.edu.
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